^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NVL-330

    i
    Other names: NVL-330
    Associations

    News

    Trials
    Company:
    Nuvalent
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) (clinicaltrials.gov)
    P1, N=120, Recruiting, Nuvalent Inc.
    New P1 trial • Metastases
    |
    NVL-330
    2years
    NVL-330 is a selective, brain-penetrant inhibitor of oncogenic HER2 exon 20 insertion mutations in preclinical models (AACR-NCI-EORTC 2022)
    NVL-330 is a wild-type EGFR-sparing, brain-penetrant small-molecule inhibitor of HER2 exon20ins in preclinical models, demonstrating the potential to address a medical need for HER2 exon 20 insertion mutant NSCLC patients.
    Preclinical • HER2 exon 20
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    HER-2 overexpression • HER-2 mutation • EGFR exon 20 insertion • EGFR wild-type • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 A775 • HER-2 exon 23 mutation
    |
    NVL-330